These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Rationale and management of hyperlipidemia of the nephrotic syndrome. Grundy SM; Vega GL Am J Med; 1989 Nov; 87(5N):3N-11N. PubMed ID: 2486542 [TBL] [Abstract][Full Text] [Related]
7. Lipid management in chronic kidney disease, hemodialysis, and transplantation. Montague T; Murphy B Endocrinol Metab Clin North Am; 2009 Mar; 38(1):223-34. PubMed ID: 19217521 [TBL] [Abstract][Full Text] [Related]
8. New insights into lipid metabolism in chronic kidney disease: what are the practical implications? Kaysen GA Blood Purif; 2009; 27(1):86-91. PubMed ID: 19169024 [TBL] [Abstract][Full Text] [Related]
9. Lipid changes and statins in chronic renal insufficiency and dialysis. Wanner C; Krane V; Metzger T; Quaschning T J Nephrol; 2001; 14 Suppl 4():S76-80. PubMed ID: 11798151 [TBL] [Abstract][Full Text] [Related]
10. [Lipoprotein disorders in chronic kidney failure, nephrotic syndrome and dialysis]. Kes P; Reiner Z; Brunetta B Lijec Vjesn; 2002; 124(11-12):372-7. PubMed ID: 12679979 [TBL] [Abstract][Full Text] [Related]
11. Identifying and managing patients with hyperlipidemia. Clark AB; Holt JM Am J Manag Care; 1997 Aug; 3(8):1211-9; quiz 1223-5. PubMed ID: 10170303 [TBL] [Abstract][Full Text] [Related]
12. Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events. Balbisi EA Med Sci Monit; 2006 Feb; 12(2):RA34-9. PubMed ID: 16449961 [TBL] [Abstract][Full Text] [Related]
13. Lipid abnormalities in chronic renal failure, nephrotic syndrome and dialysis. Kes P Acta Med Croatica; 2001; 55(4-5):177-86. PubMed ID: 12398021 [TBL] [Abstract][Full Text] [Related]
14. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Staels B; Maes M; Zambon A Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776 [TBL] [Abstract][Full Text] [Related]
15. Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives. Kamaliah MD; Sanjay LD Singapore Med J; 2001 Aug; 42(8):368-72. PubMed ID: 11764054 [TBL] [Abstract][Full Text] [Related]
16. Management of dyslipidemia in adults. Ahmed SM; Clasen ME; Donnelly JE Am Fam Physician; 1998 May; 57(9):2192-2204, 2207-8. PubMed ID: 9606309 [TBL] [Abstract][Full Text] [Related]
17. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group Am J Kidney Dis; 2003 Apr; 41(4 Suppl 3):I-IV, S1-91. PubMed ID: 12671933 [No Abstract] [Full Text] [Related]
18. Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins. Wheeler DC J Nephrol; 2001; 14 Suppl 4():S70-5. PubMed ID: 11798150 [TBL] [Abstract][Full Text] [Related]
19. [Is hyperlipidemia a factor in the progression of renal failure?]. Geiger H Z Kardiol; 1993; 82 Suppl 4():35-8. PubMed ID: 8147060 [TBL] [Abstract][Full Text] [Related]
20. Statins and renal diseases: from primary prevention to renal replacement therapy. D'Amico G J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S148-52. PubMed ID: 16565241 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]